In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Eisai Co., Ltd.

Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data

Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.

Cancer ImmunoOncology

J.P. Morgan Highlights: Major M&A Missing, But Key Takeaways For Year Ahead

The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2022’s meeting of industry leaders, investors and technology creators.

Business Strategies Commercial

Accelerated Approval Makes Big Splash In 2021 Novel Agents, Despite Crackdown On ‘Dangling’ Cancer Claims

US FDA’s accelerated approvals hit a contemporary high in 2021, accounting for one-third of novel US approvals, but the big story was the agency’s crackdown on delinquent confirmatory trials for oncology AA indications.

United States Pink Sheet Perspectives

Pink Sheet Podcast: Aduhelm Medicare Coverage, Fewer FDA Adcomms, Domestic Drug Production Effort

Pink Sheet reporter and editors discuss the CMS coverage decision for Biogen and Eisai’s Alzheimer’s treatment Aduhelm, the FDA conducting fewer advisory committee meetings in 2021 and the Defense Department’s efforts to increase domestic drug production.

Neurology Advisory Committees
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • EA Pharma Co., Ltd.
    • Eisai China Inc
    • Eisai Laboratorios
    • Eisai Mexico
    • Eisai Participacoes Ltda. (Brazil Subsidiary)
    • H3 Biomedicine
    • HI-Eisai Pharmaceutical Inc.
    • Jingyi Weixiang (Shanghai) Health Industry Development Limited
    • Liaoning TianYi Biological Pharmaceutical Co., Ltd.
    • KAN Research Institute, Inc.
    • MGI Pharma, Inc.
    • Morphotek, Inc.
    • Zycos Inc.
    • Eisai Vietnam Co., Ltd.
UsernamePublicRestriction

Register